What’s next? This is a question being asked in every household. With the U.S. federal government recently releasing guidance to states on how to re-open their economies, biotech businesses are building plans on how to re-open their doors. Everything from the White House’s three-phase plan, to signals emanating from the state governors, suggests that businesses need to plan for the...Read More
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.